Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics (DSGN)
NASDAQ:DSGN
DSGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.60 - $7.77
Previous CloseN/A
Volume97.34K
Average Volume (3M)139.45K
Market Cap
$199.26M
Enterprise ValueN/A
Total Cash (Recent Filing)$245.48M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Aug 11, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding56,768,677
10 Day Avg. Volume91,724
30 Day Avg. Volume139,453
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio-5.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.33Price Target Upside108.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsDSGN reported results from the Phase 1 study of DT-168 in healthy volunteers that supports moving into a Phase 2 biomarker study in Fuchs endothelial corneal dystrophy patients.
Financial StabilityDSGN reported $229.7M in cash and equivalents, expected to fund operating expenses into 2029.
Product DevelopmentDSGN's new product candidate, DT-216P2, contains a novel proprietary excipient which has addressed previous safety and PK issues in animal models.
Bears Say
Pipeline ProgressDSGN continues to progress preclinical activities for their myotonic dystrophy type 1 program and expects to select a candidate later in 2025.
---
Ownership Overview
19.58% Insiders
6.66% Mutual Funds
36.88% Other Institutional Investors
31.11% Public Companies and
Individual Investors
DSGN FAQ
What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $2.60 and its highest was $7.77 in the past 12 months.
What is Design Therapeutics’s market cap?
Design Therapeutics’s market cap is $199.26M.
When is Design Therapeutics’s upcoming earnings report date?
Design Therapeutics’s upcoming earnings report date is Aug 11, 2025 which is in 84 days.
How were Design Therapeutics’s earnings last quarter?
Design Therapeutics released its earnings results on May 07, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$0.03.
Is Design Therapeutics overvalued?
According to Wall Street analysts Design Therapeutics’s price is currently Undervalued.
Does Design Therapeutics pay dividends?
Design Therapeutics does not currently pay dividends.
What is Design Therapeutics’s EPS estimate?
Design Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Design Therapeutics have?
Design Therapeutics has 56,768,677 shares outstanding.
What happened to Design Therapeutics’s price movement after its last earnings report?
Design Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went up 5.706%.
Which hedge fund is a major shareholder of Design Therapeutics?
Currently, no hedge funds are holding shares in DSGN
---
Design Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.33 (108.83% Upside)
$7.33 (108.83% Upside)
Hedge Fund Trend
Increased
By 776.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.00%
12-Months-Change
Fundamentals
Return on Equity
-22.59%
Trailing 12-Months
Asset Growth
-14.82%
Trailing 12-Months
Company Description
Design Therapeutics
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
---
DSGN Stock 12 Month Forecast
Average Price Target
$7.33
▲(108.83% Upside)
Technical Analysis
Neurogene
―
Annexon Biosciences
―
Foghorn Therapeutics
―
4D Molecular Therapeutics
―
Terns Pharmaceuticals
―
---